



AN ISO 9001 & A WHO GMP CERTIFIED COMPANY



To,

Date: 30.05.2017

BSE Limited,
P.J. Towers,
Dalal Street,
Mumbai – 400001

National Stock Exchange of India Limited
Bandra-Kurla Complex
Bandra (East)
Mumbai 400051

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 30.05.2017

Ref: BSE Scrip Code 539287, NSE - ORTINLABSS

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of M/s. Ortin Laboratories Limited held on Tuesday, 30.05.2017 at 4:00 p.m. at the registered office of the company at D. No: 1-2-593/29, Ground Floor, Street No.4, Gagan Mahal Colony, Domalguda, Hyderabad - 500029, Telangana, the following were considered and approved:

1. Audited financial results for the quarter and year ended 31.03.2017. (Attached)
2. Declaration u/r 33 of SEBI (LODR) Regulations, 2015. (Attached)

The meeting concluded at 8.00 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Ortin laboratories Limited

S. Murali Krishna Murthy
Managing Director
DIN: 00540632



Encl: as above



AN ISO 9001 & A WHO GMP CERTIFIED COMPANY

SCHEDULE III OF COMPANIES ACT, 2013

PART II - AUDITED STATEMENT OF PROFIT AND LOSS FOR THE FY 2016-17

Name of the Company - Ortin Laboratories Limitd

Profit and Loss Statement for the year ended 31st March, 2017

(Rs. In Lakhs)


Particulars	STANDALONE FINANCIALS				
	Quarter Ended			Year Ended	
	31/03/2017	31/12/2016	31/03/2016	31/03/2017	31/03/2016
	Audited	Unaudited	Audited	Audited	Audited
I Revenue From Operations	1774.43	955.45	1721.68	4228.59	3976.93
II Other Income	432.30	342.13	732.22	1990.92	2374.96
III Total Revenue (I+II)	2206.73	1297.58	2453.90	6219.50	6351.89
IV Expenses					
Cost of Materials Consumed	1462.40	858.11	2243.04	3848.32	4507.64
Purchases of Stock-in-trade					
Changes in inventories of finished goods	250.47	(117.50)	(399.22)	224.37	(375.04)
Work-in-progress and Stock-in-trade					
Employee benefits expense	93.30	88.97	81.77	334.51	283.28
Finance Costs	70.41	74.65	94.04	292.87	342.13
Depreciation and Amortisation expense	42.69	43.18	40.86	170.37	164.74
Other Expenses	295.37	331.93	431.14	1247.00	1289.60
Total Expenses	2214.64	1279.34	2491.63	6117.43	6212.35
V Profit/ (Loss) before Exceptional and Extraordinary Items and tax (III-IV)	(7.91)	18.24	(37.73)	102.07	139.54
VI Exceptional Items	(0.81)	0.00	(0.82)	(0.81)	0.05
VII Profit/ (Loss) before Extraordinary Items and tax (V-VI)	(8.72)	18.24	(38.55)	101.25	139.59
VIII Extraordinary Items					
IX Profit/ (Loss) before Tax (VI-VIII)	(8.72)	18.24	(38.55)	101.24	139.59
X Tax Expense:					
Current Tax	19.48	67.14	3.84	55.72	49.50
Deferred Tax				7.00	6.70
XI Profit/ (Loss) for the period from continuing operations (VII-VIII)	(28.19)	(48.89)	(42.39)	38.50	83.39
XII Profit/ (Loss) from discontinuing operations					
XIII Tax Expense of discontinuing operations					
XIV Profit/ (Loss) from discontinuing operations after tax (XII-XIII)					
XV Profit/ (Loss) for the period (XI+XIV)					
XVI Earnings Per Share (EPS)					
Basic	(0.17)	(0.29)	(0.25)	0.23	0.49
Diluted	(0.17)	(0.29)	(0.25)	0.23	0.49

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Tuesday, 30th May, 2017.
- The Audited Financial Results for the Quarter IV and Year ended 31st March, 2017 have been prepared and reviewed by the Statutory Auditors in pursuance of Schedule III of Companies Act, 2013
- The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison.
- The results are also available on the website of the Company www.ortinlabsindia.com
- The figures of last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto third quarter of the respective financial year

Place : Hyderabad
Date : 30.05.2017

FOR ORTIN LABORATORIES LIMITED


S. MURALI KRISHNA MURTHY
 MANAGING DIRECTOR

 Corp. & Regd. Office : H.No:1-2-593/29, Ground Floor, Street No.4, Gaganmahal Colony, Near Bala Sai Baba Temple,
 Domalguda, Hyderabad - 500 029, Telangana, INDIA. Phone : +91 40 27562055 / +91 40 27567266
 website : www.ortinlabsindia.com Email : info@ortinlabsindia.com

CIN : L24110TG1986PLC006885



AN ISO 9001 & A WHO GMP CERTIFIED COMPANY

PART I - AUDITED BALANCE SHEET FOR THE FY 2016-17

Name of the Company - **Ortin Laboratories Limited**

Balance Sheet as at **31st March, 2017**

(Rupees in Lacs)

Particulars	STANDALONE	
	As at 31/03/2017	As at 31/03/2016
I EQUITY AND LIABILITIES		
1. Share Holders' Funds:		
(a) Share Capital	1694.04	1694.04
(b) Reserves and Surplus	672.52	633.21
(c) Money received against Share Warrants		
Sub-Total - Share Holders' Funds	2366.56	2327.25
2. Share Application money pending Allotment		
3. Minority Interest*		
4. Non Current Liabilities:		
(a) Long Term Borrowings	432.36	479.88
(b) Deferred Tax Liabilities (Net)	305.87	298.86
(c) Other Long Term Liabilities	373.43	781.71
(d) Long Term Provisions	25.14	20.50
4. Current Liabilities		
(a) Short Term Borrowings	1512.50	1522.08
(b) Trade Payables	331.64	281.45
total outstanding dues of micro enterprises and		
A small enterprises		
total outstanding dues of creditors other than		
B micro enterprises and small enterprises		
(c) Other Current Liabilities	788.67	820.22
(d) Short Term Provisions	4.79	1.68
TOTAL	6140.94	6533.63
II ASSETS		
1. Non-Current Assets:		
(a) Fixed Assets		
(i) Tangible Assets	2068.93	2162.73
(ii) Intangible Assets		
(iii) Capital work-in-progress	35.21	0.00
(iv) Intangible assets under development		
(b) Non-Current Investments	3.08	3.08
(c) Deferred Tax Assets (Net)		
(d) Long Term Loans and Advances	1141.04	1297.90
(e) Other Non-Current Assets		
2. Current Assets:		
(a) Current Investments		
(b) Inventories	1765.01	1684.00
(c) Trade Receivables	624.84	912.55
(d) Cash & Cash Equivalents	143.03	166.36
(e) Short Term Loans and Advances	349.73	303.06
(f) Other Current Assets	10.08	3.96
TOTAL	6140.94	6533.63

For Ortin Laboratories Limited

S. Murali Krishna Murthy

Place : **HYDERABAD**
Date : **30.05.2017**

S. MURALI KRISHNA MURTHY
MANAGING DIRECTOR





MATHESH & RAMANA
CHARTERED ACCOUNTANTS

Auditor's Report on Quarterly Financial Results and Year to Date Results of Ortin Laboratories Limited Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors
Ortin Laboratories Limited

1. We have audited the quarterly financial results of Ortin Laboratories Limited ('the Company') for the quarter ended March 31, 2017 and the year to date financial results for the year ended March 31, 2017, attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as year to date financial results have been prepared on the basis of interim financial statements, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial results which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard – 25 (AS-25), "Interim Financial Reporting", specified under section 133 of The Companies Act 2013, read with Rule 7 of Companies (Accounts) Rules 2014 and other Accounting Principles generally accepted in India.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:
 - a. are presented in accordance with the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
 - b. give a True and Fair view of the net profit and other financial information for the quarter ended March 31, 2017 as well as the year to date results for the period from April 1, 2016 to March 31, 2017.
4. The statement includes the results for the quarter ended March 31, 2017, being the balancing figure between audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the financial year which were subject to limited review by us.

Place: Hyderabad
Date: 30/05/2017



For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS

B.V. RAMANA REDDY
M. No. 026967 Partner

E-mail : mateshca@yahoo.co.in



AN ISO 9001 & A WHO GMP CERTIFIED COMPANY



Date: 30.05.2017

To,

BSE Limited,
P.J. Towers,
Dalal Street,
Mumbai – 400001

National Stock Exchange of India Limited
Bandra-Kurla Complex
Bandra (East)
Mumbai 400051

Dear Sir/Madam,

Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

I, S. Murali Krishna Murthy, Managing Director of Ortin Laboratories Limited hereby declare that, the statutory Auditors of the company, M/s. Mathesh & Ramana., Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the company for the quarter and year ended 31st March, 2017.

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you.

Yours faithfully,
For Ortin laboratories Limited


S. Murali Krishna Murthy
Managing Director
DIN: 00540632

